U.S. Markets open in 1 hr 54 mins

Detailed Research: Economic Perspectives on TESARO, Regeneron Pharmaceuticals, Pool, Zebra Technologies, Cadence Design, and TherapeuticsMD — What Drives Growth in Today's Competitive Landscape

NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TESARO, Inc. (TSRO), Regeneron Pharmaceuticals, Inc. (REGN), Pool Corporation (POOL), Zebra Technologies Corporation (ZBRA), Cadence Design Systems, Inc. (CDNS), and TherapeuticsMD, Inc. (TXMD), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

TSRO DOWNLOAD: http://MarketSourceResearch.com/register/?so=TSRO
REGN DOWNLOAD: http://MarketSourceResearch.com/register/?so=REGN
POOL DOWNLOAD: http://MarketSourceResearch.com/register/?so=POOL
ZBRA DOWNLOAD: http://MarketSourceResearch.com/register/?so=ZBRA
CDNS DOWNLOAD: http://MarketSourceResearch.com/register/?so=CDNS
TXMD DOWNLOAD: http://MarketSourceResearch.com/register/?so=TXMD

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Market Source Research, available for free download at the links above, examine TESARO, Inc. (TSRO), Regeneron Pharmaceuticals, Inc. (REGN), Pool Corporation (POOL), Zebra Technologies Corporation (ZBRA), Cadence Design Systems, Inc. (CDNS), and TherapeuticsMD, Inc. (TXMD) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed November 28th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

TESARO, INC. (TSRO) REPORT OVERVIEW

TESARO's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, TESARO reported revenue of $64.40MM vs $142.77MM (down 54.89%) and analysts estimated basic earnings per share -$2.49 vs -$0.47. For the twelve months ended December 31st, 2017 vs December 31st, 2016, TESARO reported revenue of $223.33MM vs $58.02MM (up 284.93%) and analysts estimated basic earnings per share -$9.17 vs -$7.85. Analysts expect earnings to be released on February 26th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$3.35. The estimated EPS forecast for the next fiscal year is -$9.23 and is expected to report on February 26th, 2019.

To read the full TESARO, Inc. (TSRO) report, download it here: http://MarketSourceResearch.com/register/?so=TSRO

-----------------------------------------

REGENERON PHARMACEUTICALS, INC. (REGN) REPORT OVERVIEW

Regeneron Pharmaceuticals' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Regeneron Pharmaceuticals reported revenue of $1,663.50MM vs $1,500.67MM (up 10.85%) and analysts estimated basic earnings per share $5.50 vs $3.64 (up 51.10%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Regeneron Pharmaceuticals reported revenue of $5,872.23MM vs $4,860.43MM (up 20.82%) and analysts estimated basic earnings per share $11.27 vs $8.55 (up 31.81%). Analysts expect earnings to be released on February 14th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $4.46. The estimated EPS forecast for the next fiscal year is $19.22 and is expected to report on February 14th, 2019.

To read the full Regeneron Pharmaceuticals, Inc. (REGN) report, download it here: http://MarketSourceResearch.com/register/?so=REGN

-----------------------------------------

POOL CORPORATION (POOL) REPORT OVERVIEW

Pool's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Pool reported revenue of $811.31MM vs $743.40MM (up 9.14%) and analysts estimated basic earnings per share $1.71 vs $1.20 (up 42.50%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Pool reported revenue of $2,788.19MM vs $2,570.80MM (up 8.46%) and analysts estimated basic earnings per share $4.69 vs $3.56 (up 31.74%). Analysts expect earnings to be released on February 21st, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.21. The estimated EPS forecast for the next fiscal year is $6.12 and is expected to report on February 21st, 2019.

To read the full Pool Corporation (POOL) report, download it here: http://MarketSourceResearch.com/register/?so=POOL

-----------------------------------------

ZEBRA TECHNOLOGIES CORPORATION (ZBRA) REPORT OVERVIEW

Zebra Technologies' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Zebra Technologies reported revenue of $1,092.00MM vs $935.00MM (up 16.79%) and basic earnings per share $2.37 vs -$0.23. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Zebra Technologies reported revenue of $3,722.00MM vs $3,574.00MM (up 4.14%) and analysts estimated basic earnings per share $0.33 vs -$2.65. Analysts expect earnings to be released on February 28th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $2.13. The estimated EPS forecast for the next fiscal year is $10.77 and is expected to report on February 28th, 2019.

To read the full Zebra Technologies Corporation (ZBRA) report, download it here: http://MarketSourceResearch.com/register/?so=ZBRA

-----------------------------------------

CADENCE DESIGN SYSTEMS, INC. (CDNS) REPORT OVERVIEW

Cadence Design's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Cadence Design reported revenue of $532.47MM vs $485.40MM (up 9.70%) and analysts estimated basic earnings per share $0.36 vs $0.30 (up 20.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Cadence Design reported revenue of $1,943.03MM vs $1,816.08MM (up 6.99%) and analysts estimated basic earnings per share $0.75 vs $0.71 (up 5.63%). Analysts expect earnings to be released on January 30th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.29. The estimated EPS forecast for the next fiscal year is $1.26 and is expected to report on January 30th, 2019.

To read the full Cadence Design Systems, Inc. (CDNS) report, download it here: http://MarketSourceResearch.com/register/?so=CDNS

-----------------------------------------

THERAPEUTICSMD, INC. (TXMD) REPORT OVERVIEW

TherapeuticsMD's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, TherapeuticsMD reported revenue of $3.47MM vs $4.42MM (down 21.37%) and analysts estimated basic earnings per share -$0.16 vs -$0.07. For the twelve months ended December 31st, 2017 vs December 31st, 2016, TherapeuticsMD reported revenue of $16.78MM vs $19.36MM (down 13.32%) and analysts estimated basic earnings per share -$0.37 vs -$0.46. Analysts expect earnings to be released on February 19th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.10. The estimated EPS forecast for the next fiscal year is -$0.33 and is expected to report on February 19th, 2019.

To read the full TherapeuticsMD, Inc. (TXMD) report, download it here: http://MarketSourceResearch.com/register/?so=TXMD

-----------------------------------------

ABOUT MARKET SOURCE RESEARCH

Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

REGISTERED MEMBER STATUS

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Hugo Moreau, Media Department
Office: +1 (704) 343-6361
E-mail: media@MarketSourceResearch.com

© 2018 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@MarketSourceResearch.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.